Comparison of Chikungunya Virus-Induced Disease Progression and Pathogenesis in Type-I Interferon Receptor-Deficient Mice Mouse Strains

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing a debilitating febrile illness with rheumatic disease symptoms of arthralgia and arthritis. Since its spread outside of Africa in 2005, it continues to cause outbreaks and disseminates into new territories. Intervention strategies are...

Full description

Saved in:
Bibliographic Details
Published in:Viruses 2024-10, Vol.16 (10)
Main Authors: Graham, Victoria A, Easterbrook, Linda, Rayner, Emma, Findlay-Wilson, Stephen, Flett, Lucy, Kennedy, Emma, Fotheringham, Susan, Kempster, Sarah, Almond, Neil, Dowall, Stuart
Format: Article
Language:English
Subjects:
Cell receptors
Chikungunya fever
Comparative analysis
Development and progression
Health aspects
Mice
Physiological aspects
Testing
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing a debilitating febrile illness with rheumatic disease symptoms of arthralgia and arthritis. Since its spread outside of Africa in 2005, it continues to cause outbreaks and disseminates into new territories. Intervention strategies are urgently required, including vaccination and antiviral approaches. To test efficacy, the use of small animal models is required. Two mouse strains, A129, with a deficiency in their type-I interferon (IFN) receptor, and C57BL/6 are widely used. A direct comparison of these strains alongside the wild-type parental strain of the A129 mice, 129Sv/Ev, was undertaken to assess clinical disease progression, viral loads in key tissues, histological changes and levels of sera biomarkers. Our results confirm the severe disease course in A129 mice which was not observed in the parental 129Sv/Ev strain. Of the two wild-type strains, viral loads were higher in 129Sv/Ev mice compared to C57BL/6 counterparts. Our results have established these models and parameters for the future testing of vaccines and antiviral approaches.
ISSN:1999-4915
1999-4915
DOI:10.3390/v16101534